Effects of acivicin and dipyridamole on hepatoma 3924A cells
- PMID: 6831407
Effects of acivicin and dipyridamole on hepatoma 3924A cells
Abstract
Dipyridamole inhibited the incorporation of cytidine, thymidine, uridine, and guanosine in rat hepatoma 3924A cells with 50% inhibitory concentrations of 0.2 to 0.5 microM. For deoxycytidine, the 50% inhibitory concentration was about 100 times higher (23.8 microM). Addition of a combination of cytidine, deoxycytidine, and guanosine, at an optimal concentration of 80 microM each, protected the hepatoma cells from the growth-inhibitory action of the antiglutamine drug, acivicin. The protection provided by the nucleosides was blocked by dipyridamole (6 microM), but not by nitrobenzylthionosine (30 microM). The effect on cell survival of graded concentrations of 0.25 to 1.75 microM acivicin plus dipyridamole (5 microM) and 80 microM concentrations each of cytidine, deoxycytidine, and guanosine was investigated. At an acivicin concentration of 1.75 microM, survivals in the different groups were: (a) acivicin alone, 1%; (b) acivicin plus dipyridamole, 1%; (c) acivicin plus nucleosides, 78%; and (d) acivicin plus nucleosides plus dipyridamole, 3%. Acivicin and dipyridamole were cytotoxic for hepatoma 3924A cells with 50% inhibitory concentrations of 0.5 and 20.3 microM, respectively, as measured by clonogenic assay.
Similar articles
-
Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole.Cancer Res. 1984 Aug;44(8):3355-9. Cancer Res. 1984. PMID: 6744269
-
Biochemical pharmacology of acivicin in rat hepatoma cells.Biochem Pharmacol. 1982 Nov 1;31(21):3469-73. doi: 10.1016/0006-2952(82)90628-1. Biochem Pharmacol. 1982. PMID: 7150366
-
Multi-enzyme-targeted chemotherapy by acivicin and actinomycin.Adv Enzyme Regul. 1982;20:75-96. doi: 10.1016/0065-2571(82)90009-7. Adv Enzyme Regul. 1982. PMID: 6180609
-
Acivicin in 1985.Adv Enzyme Regul. 1985;24:179-205. doi: 10.1016/0065-2571(85)90076-7. Adv Enzyme Regul. 1985. PMID: 3915184 Review.
-
Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.Pharmacol Ther. 1989;40(3):349-71. doi: 10.1016/0163-7258(89)90084-3. Pharmacol Ther. 1989. PMID: 2646650 Review.
Cited by
-
Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.Cancer Chemother Pharmacol. 1989;25(3):167-72. doi: 10.1007/BF00689577. Cancer Chemother Pharmacol. 1989. PMID: 2598406
-
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.Cancer Chemother Pharmacol. 1995;36(2):149-54. doi: 10.1007/BF00689200. Cancer Chemother Pharmacol. 1995. PMID: 7767952
-
Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.Proc Natl Acad Sci U S A. 1984 May;81(10):3200-3. doi: 10.1073/pnas.81.10.3200. Proc Natl Acad Sci U S A. 1984. PMID: 6587345 Free PMC article.
-
Interaction of [3H]dipyridamole with the nucleoside transporters of human erythrocytes and cultured animal cells.J Membr Biol. 1987;98(1):89-100. doi: 10.1007/BF01871048. J Membr Biol. 1987. PMID: 3669065
-
Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.Cancer Chemother Pharmacol. 1989;24(3):181-6. doi: 10.1007/BF00300240. Cancer Chemother Pharmacol. 1989. PMID: 2736709
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources